SONOSCAPE MEDICAL CORP. Financials SonoScape Medical Corp.
Equities
300633
CNE100002P91
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.19 CNY | +0.98% |
|
+11.41% | -12.92% |
| 04-26 | SonoScape Medical Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-12 | Sonoscape Medical Corp. Proposes Dividend for 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,393 | 1,600 | 2,020 | 3,401 | 2,870 | 2,441 | - | - |
| Enterprise Value (EV) 2 | 1,393 | 1,600 | 2,020 | 3,235 | 2,630 | 2,134 | 2,065 | 1,971 |
| P/E ratio | 95.6 x | -216 x | 51.5 x | 63.8 x | 45 x | 30.4 x | 23.8 x | 19.5 x |
| Yield | - | - | - | 0.33% | 0.68% | 0.65% | 0.8% | 1.07% |
| Capitalization / Revenue | 7.88 x | 8.94 x | 9.17 x | 13.3 x | 9.79 x | 7.17 x | 5.46 x | 4.54 x |
| EV / Revenue | 7.88 x | 8.94 x | 9.17 x | 12.6 x | 8.97 x | 6.26 x | 4.62 x | 3.67 x |
| EV / EBITDA | 72.8 x | -955 x | 52.7 x | 52.7 x | 36.1 x | 23.4 x | 17.2 x | 14 x |
| EV / FCF | - | - | - | 78.5 x | 60.9 x | 58.7 x | 24.6 x | 27.2 x |
| FCF Yield | - | - | - | 1.27% | 1.64% | 1.7% | 4.07% | 3.68% |
| Price to Book | 6.91 x | 7.76 x | 5.45 x | 8.56 x | 6.47 x | 4.87 x | 4.09 x | 3.43 x |
| Nbr of stocks (in thousands) | 405,760 | 403,836 | 401,920 | 427,862 | 430,653 | 429,414 | - | - |
| Reference price 3 | 23.90 | 25.86 | 31.93 | 54.83 | 47.30 | 41.19 | 41.19 | 41.19 |
| Announcement Date | 28/02/20 | 23/04/21 | 14/04/22 | 11/04/23 | 11/04/24 | - | - | - |
1CNY in Million2USD in Million3CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 176.8 | 179 | 220.2 | 256.2 | 293.1 | 340.7 | 447 | 537.8 |
| EBITDA 1 | 19.15 | -1.676 | 38.33 | 61.36 | 72.93 | 91.18 | 120 | 140.4 |
| EBIT 1 | 15.03 | -6.8 | 32.88 | 55.58 | 65.63 | 82.78 | 107.2 | 130.4 |
| Operating Margin | 8.5% | -3.8% | 14.93% | 21.7% | 22.39% | 24.3% | 23.99% | 24.24% |
| Earnings before Tax (EBT) 1 | 15.19 | -6.856 | 38.75 | 55.51 | 65.5 | 77.02 | 108.5 | 132.1 |
| Net income 1 | 14.32 | -7.121 | 37.69 | 53.75 | 62.82 | 73.85 | 101.9 | 124.2 |
| Net margin | 8.1% | -3.98% | 17.12% | 20.98% | 21.43% | 21.68% | 22.79% | 23.1% |
| EPS 2 | 0.2500 | -0.1200 | 0.6200 | 0.8600 | 1.050 | 1.353 | 1.731 | 2.116 |
| Free Cash Flow 1 | - | - | - | 41.2 | 43.22 | 36.33 | 84.01 | 72.53 |
| FCF margin | - | - | - | 16.08% | 14.75% | 10.67% | 18.79% | 13.49% |
| FCF Conversion (EBITDA) | - | - | - | 67.14% | 59.26% | 39.85% | 70.04% | 51.67% |
| FCF Conversion (Net income) | - | - | - | 76.65% | 68.8% | 49.2% | 82.45% | 58.39% |
| Dividend per Share 2 | - | - | - | 0.1800 | 0.3200 | 0.2678 | 0.3311 | 0.4389 |
| Announcement Date | 28/02/20 | 23/04/21 | 14/04/22 | 11/04/23 | 11/04/24 | - | - | - |
1USD in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 74.32 | 68.26 | 78.35 | 58.07 | 90.18 | - | 66.16 | 85.72 | 89.29 | 101.8 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | 16.95 | 21.56 | 19.52 | 8.011 | 17.29 | 25.38 | 15.33 | 16.03 | 16.79 | 26.12 | - | - |
| Operating Margin | - | 22.81% | 31.59% | 24.91% | 13.8% | 19.17% | - | 23.16% | 18.7% | 18.8% | 25.66% | - | - |
| Earnings before Tax (EBT) 1 | - | - | - | 19.47 | 7.935 | 17.26 | 25.28 | 15.4 | 17 | 17.75 | 27.08 | - | - |
| Net income 1 | 25.58 | - | - | 18.49 | 6.506 | 18.5 | 25.06 | 13.83 | 14.87 | 15.53 | 29.53 | - | - |
| Net margin | - | - | - | 23.6% | 11.2% | 20.51% | - | 20.9% | 17.35% | 17.4% | 29.01% | - | - |
| EPS 2 | 0.4086 | 0.2900 | 0.3220 | 0.3129 | 0.1080 | 0.3067 | - | 0.2318 | 0.2460 | 0.2570 | 0.4886 | - | - |
| Dividend per Share 2 | - | - | - | - | - | 0.3200 | - | - | - | - | 0.1834 | - | - |
| Announcement Date | 23/08/22 | 11/04/23 | 26/04/23 | 22/08/23 | 25/10/23 | 11/04/24 | 11/04/24 | 26/04/24 | - | - | - | - | - |
1USD in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 166 | 240 | 307 | 376 | 470 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | 41.2 | 43.2 | 36.3 | 84 | 72.5 |
| ROE (net income / shareholders' equity) | 7.47% | -3.36% | 16.8% | 14.6% | 15.2% | 16.4% | 17.6% | 18.2% |
| ROA (Net income/ Total Assets) | - | - | - | 11.2% | - | 13.4% | 14.2% | 14.8% |
| Assets 1 | - | - | - | 479.1 | - | 551.1 | 718.8 | 839.3 |
| Book Value Per Share 2 | 3.460 | 3.330 | 5.860 | 6.400 | 7.310 | 8.460 | 10.10 | 12.00 |
| Cash Flow per Share 2 | 0.4700 | 0.6700 | 0.7500 | 1.110 | 1.140 | 1.370 | 1.620 | 1.940 |
| Capex 1 | 22.4 | 23.9 | 23.2 | 27.6 | 24.4 | 17.9 | 23.8 | 17 |
| Capex / Sales | 12.66% | 13.35% | 10.53% | 10.77% | 8.33% | 5.25% | 5.33% | 3.17% |
| Announcement Date | 28/02/20 | 23/04/21 | 14/04/22 | 11/04/23 | 11/04/24 | - | - | - |
1USD in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
41.19
CNY
Average target price
50.14
CNY
Spread / Average Target
+21.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.92% | 2.44B | |
| -5.77% | 14.68B | |
| -40.71% | 2.71B | |
| -8.78% | 1.51B | |
| -.--% | 1.12B | |
| +40.66% | 518M | |
| +91.79% | 502M | |
| +1.67% | 183M | |
| -.--% | 168M | |
| -29.34% | 161M |
- Stock Market
- Equities
- 300633 Stock
- Financials SonoScape Medical Corp.
